The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology
机构：[1]Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Peking University People’s Hospital & Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, People’s Republic of China.[2]Affiliated Hospital of The Academy of Military Medical Sciences, Beijing, People’s Republic of China.[3]Shanghai Children’s Medical Center, Shanghai, People’s Republic of China.[4]Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Hematology and Blood Disease Hospital, Tianjin, People’s Republic of China.[5]First Affiliated Hospital of Zhejiang University, Hangzhou, People’s Republic of China.浙江大学医学院附属第一医院[6]The First Affiliated Hospital of Guangxi Medical University, Guilin, People’s Republic of China.[7]General Hospital of PLA(People’s Liberation Army of China), Beijing, People’s Republic of China.[8]Nanfang Hospital of Southern Medical University, Guangzhou, People’s Republic of China.[9]West China Hospital, Sichuan University, Chengdu, People’s Republic of China.四川大学华西医院[10]The First Affiliated Hospital of Xinjiang Medical University, Urumqi, People’s Republic of China.[11]Peking University First Hospital, Beijing, People’s Republic of China.[12]Henan Cancer Hospital, Zhengzhou, People’s Republic of China.河南省肿瘤医院[13]Anhui Provincial Hospital, Hefei, People’s Republic of China.[14]Changhai Hospital of Shanghai, Shanghai, People’s Republic of China.[15]The First Affiliated Hospital of Soochow Hospital, Soochow, People’s Republic of China.[16]Peking Union Medical College Hospital, Beijing, People’s Republic of China.[17]Tongji Medical College, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, People’s Republic of China.华中科技大学同济医学院附属协和医院[18]Peking-Tsinghua Center for Life Sciences, Beijing, People’s Republic of China.
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely used to treat malignant hematological neoplasms and non-malignant hematological disorders. Approximately, 5000 allo-HSCT procedures are performed in China annually. Substantial progress has been made in haploidentical HSCT (HID-HSCT), pre-transplantation risk stratification, and donor selection in allo-HSCT, especially after the establishment of the "Beijing Protocol" HID-HSCT system. Transplant indications for selected subgroups in low-risk leukemia or severe aplastic anemia (SAA) differ from those in the Western world. These unique systems developed by Chinese doctors may inspire the refining of global clinical practice. We reviewed the efficacy of allo-HSCT practice from available Chinese studies on behalf of the HSCT workgroup of the Chinese Society of Hematology, Chinese Medical Association and compared these studies to the consensus or guideline outside China. We summarized the consensus on routine practices of all-HSCT in China and focused on the recommendations of indications, conditioning regimen, and donor selection.
基金：
This work was supported by the Foundation for Innovative Research Groups
of the National Natural Science Foundation of China (Grant No.81621001),
the Key Program of the National Natural Science Foundation of China
(Grant No.81530046), the National key research and development plan of
China (2017YFA0104500), and the Science and Technology Project of
Guangdong Province of China (2016B030230003).
第一作者机构：[1]Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Peking University People’s Hospital & Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, People’s Republic of China.
通讯作者：
通讯机构：[1]Beijing Key laboratory of Hematopoietic Stem Cell Transplantation, Peking University People’s Hospital & Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing 100044, People’s Republic of China.[18]Peking-Tsinghua Center for Life Sciences, Beijing, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Lanping Xu,Hu Chen,Jing Chen,et al.The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology[J].JOURNAL OF HEMATOLOGY & ONCOLOGY.2018,11(1):33.doi:10.1186/s13045-018-0564-x.
APA：
Lanping Xu,Hu Chen,Jing Chen,Mingzhe Han,He Huang...&Xiaojun Huang.(2018).The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.JOURNAL OF HEMATOLOGY & ONCOLOGY,11,(1)
MLA：
Lanping Xu,et al."The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology".JOURNAL OF HEMATOLOGY & ONCOLOGY 11..1(2018):33
医学